Although the extent of contribution of ADCC/ADCP to the clinical outcomes of ipilimumab (an IgG1-form mAb targeting CTLA-4) has not been fully understood, it has been documented that human FcγR polymorphisms impact responses to ipilimumab in patients with advanced melanoma (30). The gene discussed is FCGR2A; the disease is melanoma.